Free Biopharma Daily Stock Updates - 08/02/21

$XBI $123.93 +0.40%

---

Want to access our searchable Catalyst Calendar of over 1,000 biotech stock events and more? Try BiopharmIQ for 30 days free, no credit card required. Check it out here!

---

Covid Updates

$ARCT +10.75% Arcturus Announces Approval of a Clinical Trial Application to Advance ARCT-154, a Next Generation STARR™ mRNA Vaccine Targeting the SARS-CoV-2 Delta Variant and Other Variants of Concern. source

$VXRT +11.1% FDA Clears Vaxart's IND Application for S-Only Oral Tablet COVID-19 Vaccine Candidate. source

Pipeline Updates

$FATE +2.8% Fate Therapeutics Announces Treatment of First Patient in Landmark Phase 1 Clinical Trial of FT819, the First-ever iPSC-derived CAR T-Cell Therapy source

$PLXP +3.5% PLx Pharma Inc.’s VAZALORE to Launch in Nearly 8,000 CVS Stores this Month source

$KRYS -1.0% Jeune Aesthetics Announces Initiation of Dosing in Efficacy Cohort of KB301 Phase 1 trial to Assess Improvement in Skin Quality source

$CRVS +2.4% Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2021 Financial Results source

$PSNL -1.0% Personalis, Inc. Publishes New Data Demonstrating a Novel Composite Biomarker NEOPS™ for Predicting Response to Cancer Immunotherapy in Late-Stage Melanoma Patients source

$VSTM -0.6% Verastem Oncology Reports Second Quarter 2021 Financial Results and Highlights Recent Company Progress source

$CERC +1.1% Cerecor Reports Second Quarter 2021 Financial Results and Provides Business Updates source

$IONS +1.35% Lp(a) HORIZON achieves 50% enrollment in trial to assess the safety and efficacy of pelacarsen in reducing recurrent cardiovascular events. source

$SRNE +1.6% Sorrento Receives FDA Authorization to Start Phase 1 Clinical Trial of Proprietary, "Off-the-Shelf", Allogeneic anti-CD38 DAR-T (Dimeric Antigen Receptor-T) Cell Therapy to Treat Relapsed or Refractory Multiple Myeloma. source

$MRNA -2.0% Moderna Announces First Participant Dosed in Phase 1 Study of Its IL-2 mRNA Therapeutic. source

$ETNB +7.0% 89bio Completed Target Enrollment in Histology Cohort to Evaluate BIO89-100 for the Treatment of NASH. source

$MBIO -3.5% Mustang Bio Receives European Medicines Agency PRIME Designation for MB-107 to Treat X-Linked Severe Combined Immunodeficiency in Newly Diagnosed Infants. source

$PCRX +0.50% Pacira Announces FDA Approval of Enhanced EXPAREL Manufacturing Process. source

$RNA +6.8% Avidity Biosciences Receives IND Clearance from FDA to Proceed with the Phase 1/2 MARINA™ Trial of AOC 1001 in Adults with Myotonic Dystrophy (DM1). source

$CYTK -3.0% Cytokinetics Announces Start of COURAGE-ALS, a Phase 3 Clinical Trial of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis. source

$ZNTL -5.7% Zentalis Pharmaceuticals Announces First Patient Dosed in Potentially Registrational Phase 2 Study of ZN-c3 in Patients with Uterine Serous Carcinoma. source

$ALKS +4.2% Alkermes Receives FDA Fast Track Designation for Nemvaleukin Alfa for the Treatment of Mucosal Melanoma. source

$FOLD +1.2% Amicus Therapeutics Announces European Commission Approval of Galafold® (migalastat) for Adolescents with Fabry Disease. source

$PLX +6.4% Protalix BioTherapeutics Announces Submission of Type A Meeting Request to the FDA. source

$AZN +0.25% Saphnelo (anifrolumab) approved in the US for moderate to severe systemic lupus erythematosus. source

Financial Updates

$RNA +6.8% Avidity Biosciences, Inc. Announces Proposed Public Offering of Common Stock source

---

Posted by FS/JM